HRMY vs. BMY

Last updated Apr 2, 2026

Compare and contrast key facts about Harmony Biosciences Holdings, Inc. (HRMY) and Bristol-Myers Squibb Company (BMY).

Performance

HRMY vs. BMY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Harmony Biosciences Holdings, Inc. (HRMY) and Bristol-Myers Squibb Company (BMY). The values are adjusted to include any dividend payments, if applicable.

HRMY vs. BMY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
HRMY Harmony Biosciences Holdings, Inc.	-25.28%	8.75%	6.53%	-41.38%	29.22%	17.95%	-2.32%
BMY Bristol-Myers Squibb Company	15.79%	0.11%	15.81%	-26.14%	18.98%	2.88%	-0.15%

Fundamentals

Market Cap HRMY : $1.64B BMY : $125.99B
EPS HRMY : $3.33 BMY : $3.46
PE Ratio HRMY : 8.39 BMY : 17.84
PEG Ratio HRMY : 0.08 BMY : 1.02
PS Ratio HRMY : 1.89 BMY : 2.61
PB Ratio HRMY : 1.89 BMY : 2.26
Total Revenue (TTM) HRMY : $868.45M BMY : $48.19B
Gross Profit (TTM) HRMY : $670.11M BMY : $30.43B
EBITDA (TTM) HRMY : $238.25M BMY : $13.82B

Returns By Period

In the year-to-date period, HRMY achieves a -25.28% return, which is significantly lower than BMY's 15.79% return.

HRMY

• 1D: -0.18%
• 1M: -3.25%
• YTD: -25.28%
• 6M: 3.86%
• 1Y: -13.76%
• 3Y*: -5.04%
• 5Y*: -2.72%
• 10Y*: —

BMY

• 1D: 1.78%
• 1M: -0.98%
• YTD: 15.79%
• 6M: 33.50%
• 1Y: 8.90%
• 3Y*: 0.70%
• 5Y*: 3.49%
• 10Y*: 2.90%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

HRMY vs. BMY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HRMY

HRMY Risk / Return Rank: 25
HRMY Sharpe Ratio Rank: 26
HRMY Sortino Ratio Rank: 25
HRMY Omega Ratio Rank: 24
HRMY Calmar Ratio Rank: 26
HRMY Martin Ratio Rank: 23

BMY

BMY Risk / Return Rank: 47
BMY Sharpe Ratio Rank: 52
BMY Sortino Ratio Rank: 45
BMY Omega Ratio Rank: 44
BMY Calmar Ratio Rank: 47
BMY Martin Ratio Rank: 45

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

HRMY vs. BMY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Harmony Biosciences Holdings, Inc. (HRMY) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	HRMY	BMY	Difference
Sharpe ratio Return per unit of total volatility	-0.33	0.31	-0.64
Sortino ratio Return per unit of downside risk	-0.18	0.64	-0.82
Omega ratio Gain probability vs. loss probability	0.97	1.08	-0.10
Calmar ratio Return relative to maximum drawdown	-0.46	0.25	-0.70
Martin ratio Return relative to average drawdown	-0.99	0.39	-1.38
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

HRMY vs. BMY - Sharpe Ratio Comparison

The current HRMY Sharpe Ratio is -0.33, which is lower than the BMY Sharpe Ratio of 0.31. The chart below compares the historical Sharpe Ratios of HRMY and BMY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	HRMY	BMY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.33	0.31	-0.64
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.05	0.15	-0.20
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.12	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.09	0.35	-0.45

Correlation

The correlation between HRMY and BMY is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

HRMY vs. BMY - Dividend Comparison

HRMY has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.03%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
HRMY Harmony Biosciences Holdings, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
BMY Bristol-Myers Squibb Company	4.03%	4.60%	4.24%	4.44%	3.00%	2.36%	3.69%	2.55%	3.08%	2.55%	1.95%	2.17%

Drawdowns

HRMY vs. BMY - Drawdown Comparison

The maximum HRMY drawdown since its inception was -68.48%, roughly equal to the maximum BMY drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for HRMY and BMY.

Drawdown Indicators

	HRMY	BMY	Difference
Max Drawdown Largest peak-to-trough decline	-68.48%	-72.03%	+3.55%
Max Drawdown (1Y) Largest decline over 1 year	-34.49%	-25.79%	-8.70%
Max Drawdown (5Y) Largest decline over 5 years	-68.48%	-47.67%	-20.81%
Max Drawdown (10Y) Largest decline over 10 years	—	-47.67%	—
Current Drawdown Current decline from peak	-54.10%	-12.07%	-42.03%
Average Drawdown Average peak-to-trough decline	-34.76%	-22.40%	-12.36%
Ulcer Index Depth and duration of drawdowns from previous peaks	15.96%	16.06%	-0.10%

Volatility

HRMY vs. BMY - Volatility Comparison

Harmony Biosciences Holdings, Inc. (HRMY) has a higher volatility of 7.89% compared to Bristol-Myers Squibb Company (BMY) at 6.68%. This indicates that HRMY's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	HRMY	BMY	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.89%	6.68%	+1.21%
Volatility (6M) Calculated over the trailing 6-month period	31.01%	19.39%	+11.62%
Volatility (1Y) Calculated over the trailing 1-year period	41.98%	28.61%	+13.37%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	50.61%	23.68%	+26.93%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	52.82%	25.08%	+27.74%

Financials

HRMY vs. BMY - Profitability Comparison

The chart below illustrates the profitability comparison between Harmony Biosciences Holdings, Inc. and Bristol-Myers Squibb Company over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

HRMY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Harmony Biosciences Holdings, Inc. reported a gross profit of 175.23M and revenue of 243.78M. Therefore, the gross margin over that period was 71.9%.

BMY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported a gross profit of 6.24B and revenue of 12.50B. Therefore, the gross margin over that period was 49.9%.

HRMY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Harmony Biosciences Holdings, Inc. reported an operating income of 38.56M and revenue of 243.78M, resulting in an operating margin of 15.8%.

BMY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported an operating income of 1.47B and revenue of 12.50B, resulting in an operating margin of 11.8%.

HRMY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Harmony Biosciences Holdings, Inc. reported a net income of 59.03M and revenue of 243.78M, resulting in a net margin of 24.2%.

BMY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported a net income of 1.09B and revenue of 12.50B, resulting in a net margin of 8.7%.